Randomized Phase 2 Trial of Inhaled Furosemide on the dyspnea associated with Cancer

INTERVENTION: Nebulized furosemide 40mg at a time, 3 times a day on 2 consecutive days Nebulized 0.9% saline 4ml at a time, 3 times a day on 2 consecutive days CONDITION: Dyspnea associated with Cancer PRIMARY OUTCOME: The worst dyspneic sensation as measured on NRS between on the previous day of the treatment and on the final day of the treatment INCLUSION CRITERIA: I.The first stage 1) Age >= 20 2) Notified cancer patients 3) The patients having cancer dyspnea mainly caused by one of the following conditions: pleural effusion, primary lung tumor, metastatic lung tumor, cough, air way stenosis, and phrenic nerve paralysis, with or without chronic obstructive lung disease II.The second stage 1) Written informed consent 2) The patients with the sensation of dyspnea, the worst score of which is 6 or more on NRS, on 2 consecutive days 3) Expected survival of more than 2 weeks 4) The patients with the sensation of dyspnea after the treatment of rapid onset oral morphine 5) PS(ECOG)1‐3 6) Hospitalized patients 7) Eligible for the first stage inclusion criteria